Application of Myriberine A in preparing antituberculous medicines

An anti-tuberculosis and drug technology, applied in the direction of antibacterial drugs, pharmaceutical formulas, medical preparations containing active ingredients, etc., can solve the problems of non-standard treatment and management of tuberculosis patients, difficulties in tuberculosis prevention and control, and achieve tuberculosis suppression The effect of strong activity, highlighting substantive characteristics, and expanding categories

Inactive Publication Date: 2013-10-23
ZIBO DINGLI PATENT INFORMATION CONSULTING CO LTD
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the irregular treatment and management of tuberculosis patients, irregular chemotherapy and abuse of anti-tuberculosis drugs, the drug resistance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Myriberine A in preparing antituberculous medicines
  • Application of Myriberine A in preparing antituberculous medicines
  • Application of Myriberine A in preparing antituberculous medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Embodiment 1: the preparation of compound Myriberine A tablet involved in the present invention:

[0016] Take 5 grams of compound Myriberine A, add 195 grams of dextrin, mix well, and make 1000 tablets by conventional compression.

Embodiment 2

[0017] Embodiment 2: the preparation of the compound Myriberine A capsule involved in the present invention:

[0018] Get 5 grams of compound Myriberine A, add 195 grams of starch, mix well, and make 1000 capsules.

experiment example 1

[0019] Experimental Example 1 Determination of Absolute Concentration of Myriberine A Anti-Bacillus Calmette-Guerin (BCG) by Solid Medium Dilution Method

[0020] Scrape the BCG culture from the slant, add it to 3ml Middlebrook7H9 broth medium, add a small amount of glass beads, tighten the test tube cap, vibrate and grind vigorously on the vortex oscillator, and compare it with the standard McFarland turbidimetric tube (MacFarland No.1) Turbidity, that is, to prepare 1mg / ml bacillus Calmette-Guerin (BCG) bacterial suspension.

[0021] Make Myriberine A into a high-concentration stock solution with DMSO, dilute the stock solution to the required concentration with 5% Tween-80 sterile ultrapure water, and add the diluted Myriberine A to 4ml Middlebrook7H11 agar medium according to the required dose (The medium has been sterilized by high pressure steam at 121°C for 15 minutes, cooled to 50-55°C), mixed evenly, and made to contain Myriberine A, the concentrations are 6.0ug / ml, 4...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of Myriberine A in preparing antituberculous medicines. The application of the Myriberine A aims at current situations that high tuberculosis incidence and appearance of multi-drug resistant strains of tubercle bacillus result in the rising tendency in the incidence and mortality rate of the tuberculosis, and the Myriberine A is found to have remarkable tubercle bacillus inhibitory activity and a good application prospect. The application of the Myriberine A in preparing the antituberculous medicines is disclosed for the first time. The framework type is a brand-new framework type, and therefore the Myriberine A has unexpected tubercle bacillus inhibitory activity. The Myriberine A has prominent substantive features and is impossibly revealed by other compounds, and has remarkable progresses when used for preventing and treating tubercle bacillus infection.

Description

technical field [0001] The present invention relates to a new application of compound Myriberine A, in particular to the application of Myriberine A in the preparation of anti-tuberculosis drugs. Background technique [0002] In recent years, the incidence of tuberculosis in the world has shown an increasing trend. According to the World Health Organization (WHO) estimates, the population infected by Mycobacterium tuberculosis (MTB) accounts for one-third of the world's population, of which 5-10% Infected people become TB patients. There are 1.3 million cases of active tuberculosis patients in my country every year, including about 600,000 cases of infectious tuberculosis, and about 600,000 cases of infectious tuberculosis. It is one of the countries with a high burden of tuberculosis in the world. [0003] Since the advent of anti-tuberculosis drugs one after another, the treatment of tuberculosis has played an epoch-making change. However, due to the irregular treatment ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/519A61P31/06
Inventor 高忠青
Owner ZIBO DINGLI PATENT INFORMATION CONSULTING CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap